Tevogen Bio Holdings Inc. Announces International Patent Application Publication for AI Technology in Peptide Prediction

Reuters
19 Jul
<a href="https://laohu8.com/S/TVGNW">Tevogen Bio Holdings Inc.</a> Announces International Patent Application Publication for AI Technology in Peptide Prediction

Tevogen Bio Holdings Inc. has announced that the International Bureau of the World Intellectual Property Organization (WIPO) has published its international patent application (Publication No. WO 2025/129197). The application is titled "Systems and Methods for Predicting Immunologically Active Peptides with Machine Learning Models" and covers technology developed by Tevogen.AI. This technology uses machine learning algorithms to rapidly and accurately identify peptides with strong immune system interactions, aiding in the development of targeted therapies for various diseases.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9496936-en) on July 18, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10